Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 activity and levels can be downregulated in several tumors and cancer cell types, indicating poor prognosis and treatment resistance.
|
30474528 |
2019 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Par-4 down-regulation is often observed in cancer while up-regulation is characteristic of neurodegenerative conditions such as Alzheimer's disease.
|
30518159 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Par-4 induces apoptosis selectively in various types of cancer cells but not normal cells.
|
29695515 |
2018 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Previous study revealed that the expression of PAR4 was increased in colorectal cancer tissues compared with the associated normal tissues, particularly in positive lymph node and poorly differentiated types of cancer.
|
30333860 |
2018 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
We report that the anti-malarial drug, chloroquine (CQ), is a robust inducer of Par-4 secretion from normal cells in mice and cancer patients in a clinical trial.
|
28076793 |
2017 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Transcripts for genes (<i>F2RL3, EMILIN1</i> and <i>CDC42BPA</i>) previously identified as being differentially methylated or expressed in smoking or smoking-related cancers were overexpressed in smokers compared to non-smokers and the expression of transcripts for genes (<i>HERPUD1, GAB2, FAM167A</i> and <i>GLS</i>) previously associated with stress response, autoimmune disease and cancer were associated with telomere length.
|
29207374 |
2017 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
This mutant AATF along with its interactome consisting of SP1, DNMT3B and Par-4 ensures cancer cell DNA methylation required for down-regulation of tumor suppressor genes.
|
25231211 |
2015 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Many studies have highlighted the importance of Par-4 not only in preventing cancer development/recurrence but also as a promising anticancer therapeutic agent.
|
25001535 |
2014 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, differential expression of PAR4 in esophageal squamous cancer was measured by real-time PCR (n = 28), western blot and tissue microarrays (n = 78).
|
25030438 |
2014 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Fbxo45-mediated degradation of the tumor-suppressor Par-4 regulates cancer cell survival.
|
24992930 |
2014 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Experimental evidence indicates that prostate apoptosis response-4 (Par-4, also known as PAWR) is a key regulator of cancer cell survival and may be a target for cancer-selective targeted therapeutics.
|
23760770 |
2013 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Endoplasmic reticulum-stress and higher levels of protein kinase A in tumor cells confer the coveted feature of cancer selective response to extracellular and intracellular Par-4, respectively.
|
22552839 |
2012 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4.
|
22962598 |
2012 |
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
PAR mRNA expression was higher in cancer, and protein expression was increased in PAR-1 (45%), PAR-2 (42%), and PAR-4 (68%), compared to normal glands.
|
17373694 |
2007 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The unique ability of Par-4 to induce apoptosis in cancer cells but not normal cells and the ability of Par-4 antisense or dominant-negative mutant to abrogate apoptosis in neurodegenerative disease paradigms makes it an appealing candidate for molecular therapy of cancer and neuronal diseases.
|
12565819 |
2003 |